Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Abstract Background Lymphovascular space invasion (LVSI) is the first step of hematogenous metastasis. Exploration of the differential miRNA expression profiles between LVSI-positive and LVSI-negative ovarian cancer tissues may help to identify key miRNAs involved in the hematogenous metastasis of o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Li, Huiran Yue, Wenzhi Li, Guohua Zhu, Tingting Zhu, Ruifang Chen, Xin Lu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Ovarian cancer Lymphovascular space invasion MicroRNA Bevacizumab Prognosis Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/c1af4fe79e09471eab7e38649c8a4019
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1af4fe79e09471eab7e38649c8a4019
record_format	dspace
spelling	oai:doaj.org-article:c1af4fe79e09471eab7e38649c8a40192021-11-28T12:29:23ZBevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression10.1186/s13048-021-00915-91757-2215https://doaj.org/article/c1af4fe79e09471eab7e38649c8a40192021-11-01T00:00:00Zhttps://doi.org/10.1186/s13048-021-00915-9https://doaj.org/toc/1757-2215Abstract Background Lymphovascular space invasion (LVSI) is the first step of hematogenous metastasis. Exploration of the differential miRNA expression profiles between LVSI-positive and LVSI-negative ovarian cancer tissues may help to identify key miRNAs involved in the hematogenous metastasis of ovarian cancer. This study is aimed to identify microRNAs (miRNAs) that are differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tissues, followed by exploring their association with bevacizumab response in ovarian cancer patients. Methods The Cancer Genome Altas (TGGA) dataset was used to identify the differentially expressed miRNAs between LVSI-positive and LVSI-negative ovarian cancer tissues. The prognostic value of the differentially expressed miRNAs was determined using GSE140082 dataset. Results We showed that miR-25 and miR-142 were differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tumors. Kaplan-Meier analysis indicated that high miR-25 expression was associated with increased progression free survival (PFS) and extended overall survival (OS). Moreover, patients with low miR-25 expression benefited significantly from bevacizumab treatment in terms of PFS. A similar trend was observed in terms of OS though without reaching statistical significance. In contrast, no significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of PFS and OS. There was no significant correlation between miR-142 expression and PFS. In contrast, high miR-142 expression was associated with reduced OS. Moreover, patients with high miR-142 expression benefited significantly from bevacizumab treatment in terms of PFS and OS. However, bevacizumab treatment conferred no significant improvements in both PFS and OS in patients with low miR-142 expression. The nomogram for PFS indicated that miR-25 expression had a larger contribution to PFS than debulking status and bevacizumab treatment. And the nomogram for OS illustrated both miR-25 expression and miR-142 expression as sharing a larger contribution to OS than bevacizumab treatment and debulking status. Conclusion In conclusion, miR-25 expression correlates with a better PFS and OS in ovarian cancer. Patients with low miR-25 expression and high miR-142 expression could benefit from bevacizumab treatment significantly.Jun LiHuiran YueWenzhi LiGuohua ZhuTingting ZhuRuifang ChenXin LuBMCarticleOvarian cancerLymphovascular space invasionMicroRNABevacizumabPrognosisGynecology and obstetricsRG1-991ENJournal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ovarian cancer Lymphovascular space invasion MicroRNA Bevacizumab Prognosis Gynecology and obstetrics RG1-991
spellingShingle	Ovarian cancer Lymphovascular space invasion MicroRNA Bevacizumab Prognosis Gynecology and obstetrics RG1-991 Jun Li Huiran Yue Wenzhi Li Guohua Zhu Tingting Zhu Ruifang Chen Xin Lu Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
description	Abstract Background Lymphovascular space invasion (LVSI) is the first step of hematogenous metastasis. Exploration of the differential miRNA expression profiles between LVSI-positive and LVSI-negative ovarian cancer tissues may help to identify key miRNAs involved in the hematogenous metastasis of ovarian cancer. This study is aimed to identify microRNAs (miRNAs) that are differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tissues, followed by exploring their association with bevacizumab response in ovarian cancer patients. Methods The Cancer Genome Altas (TGGA) dataset was used to identify the differentially expressed miRNAs between LVSI-positive and LVSI-negative ovarian cancer tissues. The prognostic value of the differentially expressed miRNAs was determined using GSE140082 dataset. Results We showed that miR-25 and miR-142 were differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tumors. Kaplan-Meier analysis indicated that high miR-25 expression was associated with increased progression free survival (PFS) and extended overall survival (OS). Moreover, patients with low miR-25 expression benefited significantly from bevacizumab treatment in terms of PFS. A similar trend was observed in terms of OS though without reaching statistical significance. In contrast, no significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of PFS and OS. There was no significant correlation between miR-142 expression and PFS. In contrast, high miR-142 expression was associated with reduced OS. Moreover, patients with high miR-142 expression benefited significantly from bevacizumab treatment in terms of PFS and OS. However, bevacizumab treatment conferred no significant improvements in both PFS and OS in patients with low miR-142 expression. The nomogram for PFS indicated that miR-25 expression had a larger contribution to PFS than debulking status and bevacizumab treatment. And the nomogram for OS illustrated both miR-25 expression and miR-142 expression as sharing a larger contribution to OS than bevacizumab treatment and debulking status. Conclusion In conclusion, miR-25 expression correlates with a better PFS and OS in ovarian cancer. Patients with low miR-25 expression and high miR-142 expression could benefit from bevacizumab treatment significantly.
format	article
author	Jun Li Huiran Yue Wenzhi Li Guohua Zhu Tingting Zhu Ruifang Chen Xin Lu
author_facet	Jun Li Huiran Yue Wenzhi Li Guohua Zhu Tingting Zhu Ruifang Chen Xin Lu
author_sort	Jun Li
title	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
title_short	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
title_full	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
title_fullStr	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
title_full_unstemmed	Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression
title_sort	bevacizumab confers significant improvements in survival for ovarian cancer patients with low mir-25 expression and high mir-142 expression
publisher	BMC
publishDate	2021
url	https://doaj.org/article/c1af4fe79e09471eab7e38649c8a4019
work_keys_str_mv	AT junli bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT huiranyue bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT wenzhili bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT guohuazhu bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT tingtingzhu bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT ruifangchen bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression AT xinlu bevacizumabconferssignificantimprovementsinsurvivalforovariancancerpatientswithlowmir25expressionandhighmir142expression
_version_	1718407980761743360

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Ejemplares similares